Cancer Drug Developer GeneSegues Therapeutics Names Laura Morris Brod as CEO

Company Positioned to Accelerate Growth Plans

GeneSegues Therapeutics, a leader in innovative RNAi and DNA therapeutics for cancer and infectious diseases, today announced the addition of its new CEO.

“We’re very excited to have Laura Brod join us at this important juncture and lead our company forward,” said Dr. Gretchen Unger, founder and Chief Scientific Officer of GeneSegues. “Laura has excelled in every facet of her professional life, and is a perfect complement to our team as we execute against our core mission of developing novel cancer therapies which can significantly improve treatment outcomes.” Chairman of the Board John Stapleton says that Laura brings a wealth of talent and possibility to the team: “Her proven abilities to build relationships, develop effective business strategies, and guide complex processes are critical at this time as we transition from a research stage company to a development stage company,” he said.

Laura Brod has been the catalyst and owner of three start-up businesses in a variety of industries and has specialized in strategy, communication, and collaborative partner engagement. She is currently an at-large member of the University of Minnesota Board of Regents with responsibilities including chair of the University’s Audit Committee. She was a member of the Minnesota House of Representatives from 2002 to 2010, during which time she served as Assistant Majority Leader. Brod has been honored by a number of national and international organizations, including the Aspen Global Fellowship, the German Marshall Fellowship and the Aspen-Rodel Fellowship, and has participated in the Canadian Rising Leaders and Swiss Young Leaders programs.

“I’m thrilled about the opportunity to work with the industry’s most innovative RNAi nanocapsule technology and capture its full potential. GeneSegues has a great mission, phenomenal team, and critical science and technology,” said Brod. “I am confident that the company is on the path to make a real difference in cancer, and I am ready to help make that happen.”

About GeneSegues Therapeutics

Minneapolis-based GeneSegues Therapeutics is a biopharmaceutical company specializing in the innovation of DNA and RNAi cancer therapeutics, delivered with proprietary sub-50 nanometer (s50) nanocapsule technology. The company’s lead product is GS-10, an s50-encapsulated RNAi therapeutic for the treatment of a range of solid tumor cancers including head and neck, prostate and breast and their related metastases.

GeneSegues | 3180 High Point, Chaska, MN 55318

Share This Post

More To Explore